Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review)

International Journal of Oncology

Volumn 13, Issue 2, 1998, Pages 305-318

  Maio, Michele ^a   Brasoveanu, Lorelei Irina ^a   Coral, Sandra ^a   Sigalotti, Luca ^a   Lamaj, Elda ^a   Gasparollo, Aldo ^a   Visintin, Alberto ^a   Altomonte, Maresa ^a   Fonsatti, Ester ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

CD59; Complement; Glycosyl phosphatidylinositol anchor; Immunotherapy; Protectin; Solid tumors

Indexed keywords

CD59 ANTIGEN; COMPLEMENT;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CHROMOSOME 11; COMPLEMENT ACTIVATION; GENE EXPRESSION REGULATION; GENE STRUCTURE; IMMUNOHISTOCHEMISTRY; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

EID: 0031821575     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.2.305     Document Type: Review

References (118)

1. Morgan BP: Physiology and pathophysiology of complement: progress and trends. Crit Rev Clin Lab Sci 32: 265-298, 1995.
2. Nicholson-Weller A and Wang CE: Structure and function of decay accelerating factor CD55. J Lab Clin Med 123: 485-491, 1994.
3. Liszewski MK, Post TW and Atkinson JP: Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 9: 431-455, 1991.
4. Ahearn JM and Fearon DT: Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 46: 183-219, 1989.
5. Zalman LS, Wood LM and Müller-Eberhard HJ: Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci USA 83: 6975-6979, 1986.
6. Sugita Y, Nakano Y and Tomita M: Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem 104: 633-637, 1988.
7. Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA and Parker CJ: Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 84: 7-17, 1989.
8. Harada R, Okada N, Fujita T and Okada H: Purification of 1F5 antigen that prevents complement attack on homologous cell membranes. J Immunol 144: 1823-1828, 1990.
9. Rollins SA and Sims PJ: The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 144: 3478-3483, 1990.
10. Hadam MR: Cluster report: CD59. In: Leucocyte Typing IV. White Cell Differentiation Antigens. Knapp W, Dörken B, Gilks WR, Rieber EP, Schmidt RE, Stein H and von den Borne AEGK (eds). Oxford University Press, Oxford, pp720-722, 1989.
11. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H and Lachmann PJ: Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71: 1-9, 1990.
12. Stefanova I, Hilgert I, Kristofova H, Brown R, Low MG and Horejsi V: Characterization of a broadly expressed human leukocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol. Mol Immunol 26: 153-161, 1989.
13. Groux H, Huet S, Aubrit F, Tran HC, Boumsell L and Bernard A: A 19-kDa human erythrocyte molecule H19 is involved in rosettes, present on nucleated cells, and required for T cell activation. J Immunol 142: 3013-3020, 1989.
14. Sugita Y, Mazda T and Tomita M: Amino-terminal amino acid sequence and chemical and functional properties of a membrane attack complex-inhibitory factor from human erythrocyte membranes. J Biochem 106: 589-592, 1989.
15. Okada N, Harada R, Fujita T and Okada H: Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement. J Immunol 143: 2262-2266, 1989.
16. Forsberg UH, Bazil V, Stefanova I and Schröder J: Gene for human CD59 (likely Ly-6 homologue) is located on the short arm of chromosome 11. Immunogenetics 30: 188-193, 1989.
17. Petranka JG, Fleenor DE, Sykes K, Kaufman RE and Rosse WF: Structure of the CD59-encoding gene: further evidence of a relationship to murine lymphocyte antigen Ly-6 protein. Proc Natl Acad Sci USA 89: 7876-7879, 1992.
18. Tone M, Walsh LA and Waldmann H: Gene structure of human CD59 and demonstration that discrete mRNAs are generated by alternative polyadenylation. J Mol Biol 227: 971-976, 1992.
19. Holguin MH, Martin CB, Eggett T and Parker CJ: Analysis of the gene that encodes the complement regulatory protein, membrane inhibitor of reactive lysis (CD59). J Immunol 157: 1659-1668, 1996.
20. Kumar S, Vinci JM, Pytel BA and Baglioni C: Expression of messenger RNAs for complement inhibitors in human tissues and tumors. Cancer Res 53: 348-353, 1993.
21. Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ and Waldmann H: CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 170: 637-654, 1989.
22. Sugita Y and Masuho Y: CD59: its role in complement regulation and potential for therapeutic use. Immunotechnology 1: 157-168, 1995.
23. Davies A and Morgan BP: Expression of the glycosylphosphatidylinositol-linked complement-inhibiting protein CD59 antigen in insect cells using a baculovirus vector. Biochem J 295: 889-896, 1993.
24. Okada N, Harada R, Fujita T and Okada H: A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol 1: 205-208, 1989.
25. Meri S, Lehto T, Sutton CW, Tyynela J and Baumann M: Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis. Biochem J 316: 923-935, 1996.
26. Maxwell SE, Ramalingam S, Gerber LD, Brink L and Udenfriend S: An active carbonyl formed during glycosylphosphatidylinositol addition to a protein is evidence of catalysis by a transamidase. J Biol Chem 270: 19576-19582, 1995.
27. Rudd PM, Morgan BP, Wormald MR, Harvey DJ, van den Berg CW, Davis SJ, Ferguson MAJ and Dwek RA: The glycosylation of the complement regulatory protein, human erythrocyte CD59. J Biol Chem 272: 7229-7244, 1997.
28. Anderson RGW: Plasmalemmal caveolae and GPI-anchored membrane proteins. Curr Opin Cell Biol 5: 647-652, 1993.
29. Deckert M, Ticchioni M and Bernard A: Endocytosis of GPI-anchored proteins in human lymphocytes: role of glycolipid-based domains, actin cytoskeleton, and protein kinases: J Cell Biol 133: 791-799, 1996.
30. Rushmere NK, Harrison RA, van den Berg CW and Morgan BP: Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site. Biochem J 304: 595-601, 1994.
31. Fletcher CM, Harrison RA, Lachmann PJ and Neuhaus D: Sequence-specific H-NMR assignments and folding topology of human CD59. Protein Sci 2: 2015-2027, 1993.
32. Kieffer B, Driscoll PC, Campbell ID, Willis AC, van der Merwe PA and Davis SJ: Three-dimensional solution structure of the extracellular region of the complement regulatory protein CD59, a new cell-surface protein domain related to snake venom neurotoxins. Biochemistry 33: 4471-4482, 1994.
33. Yu J, Abagyan R, Dong S, Gilbert A, Nussenzweig V and Tomlinson S: Mapping the active site of CD59. J Exp Med 185: 745-753, 1997.
34. Bodian DL, Davis SJ, Morgan BP and Rushmere NK: Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59. J Exp Med 185: 507-516, 1997.
35. Yu J, Dong S, Rushmere NK, Morgan BP, Abagyan R and Tomlinson S: Mapping the regions of the complement inhibitor CD59 responsible for its species selective activity. Biochemistry 36: 9423-9428, 1997.
36. Rushmere NK, Tomlinson S and Morgan BP: Expression of rat CD59: functional analysis confirms, lack of species selectivity and reveals that glycosylation is not required for function. Immunology 90: 640-646, 1997.
37. Nakano Y, Noda K, Endo T, Kobata A and Tomita M: Structural study on the glycosyl-phosphatidylinositol anchor and the asparagine-linked sugar chain of a soluble form of CD59 in human urine. Arch Biochem Biophys 311: 117-126, 1994.
38. Suzuki H, Yamaji N, Egashira A, Yasunaga K, Sugita Y and Masuho Y: Effect of the sugar chain of soluble recombinant CD59 on complement inhibitory activity. FEBS Lett 399: 272-276, 1996.
39. Rother RP, Zhao J, Zhou Q and Sims PJ: Elimination of potential sites of glycosylation fails to abrogate complement regulatory function of cell surface CD59. J Biol Chem 271: 23842-23845, 1996.
40. Miyata T, Takeda J, Iida Y, Yamada N, Inoue N, Takahashi M, Maeda K, Kitani T and Kinoshita T: The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 259: 1318-1320, 1993.
41. Doering TL, Masterson WJ, Hart GW and Englund PT: Biosynthesis of glycosylphosphatidylinositol membrane anchors. J Biol Chem 265: 611-614, 1990.
42. Brasoveanu LI, Altomonte M, Fonsatti E, Colizzi F, Coral S, Nicotra MR, Cattarossi I, Cattelan A, Natali PG and Maio M: Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab Invest 74: 33-42, 1996.
43. Gorter A, Blok VT, Haasnoot WHB, Ensink NG, Daha MR and Fleuren GJ: Expression of CD46, CD55 and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis. Lab Invest 74: 1039-1049, 1996.
44. Bjørge L, Hakulinen J, Wahlström T, Matre R and Meri S: Complement-regulatory proteins in ovarian malignancies. Int J Cancer 70: 14-25, 1997.
45. Shevach EM and Korty EP: Ly-6: a multigene family in search of a function. Immunol Today 10: 195-200, 1989.
46. Davies A and Lachmann PJ: Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res 12: 258-275, 1993.
47. Powell MB, Marchbank KJ, Rushmere NK, van den Berg CW and Morgan BP: Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59. J Immunol 158: 1692-1702, 1997.
48. Hinchliffe SJ, Rushmere NK, Hanna SM and Morgan BP: Molecular cloning and functional characterization of the pig analogue of CD59: relevance to xenotransplantation. J Immunol 160: 3924-3932, 1998.
49. Williams AF, Tsc AG-D and Gagnon J: Squid glycoproteins with structural similarities to Thy-1 and Ly-6 antigens. Immunogenetics 27: 265-272, 1988.
50. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Danø K, Appella E and Blasi F: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9; 467-474, 1990.
51. Mao M, Yu M, Tong J-H, Ye J, Zhu J, Huang Q-H, Fu G, Yu L, Zhao S-Y, Waxman S, Lanotte M, Wang Z-Y, Tan J-Z, Tan CC, Chan S-J and' Chen Z: RIG-E, a human homolog of the murine Ly-6 family, is induced by retinoic acid during the differentiation of acute promyelocytic leukemia cell. Proc Natl Acad Sci USA 93: 5910-5914, 1996.
52. Rother RP, Rollins SA, Fodor WL, Albrecht J-C, Setter E, Fleckenstein B and Squinto SP: Inhibition of complement-mediated cytolysis by the terminal complement inhibitor of herpes virus saimiri. J Virol 68: 730-737, 1994.
53. Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH and Saifuddin M: Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol 155: 4376-4381, 1995.
54. Saifuddin M, Parker CJ, Peoples ME, Gorny MK, Pazner-Zolla S, Ghassemi M, Rooney IA, Atkinson JP and Spear GT: Role of virion-associatcd glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolated of HIV-I. J Exp Med 182: 501-509, 1995.
55. Parolini I, Sargiacomo M, Lisanti MP and Pcschle C: Signal transduction and glycophosphatidylinositol-linked proteins (LYN, LCK, CD4, CD45, G proteins, and CD55) selectively localize in triton-insoluble plasma membrane domains of human leukemic cell lines and normal granulocytes. Blood 87: 3783-3794, 1996.
56. Brown D: The tyrosine kinase connection: how GPI-anchored proteins activate T cells. Curr Opin Immunol 5: 349-354, 1993.
57. Solomon KR, Rudd CE and Finberg RW: The association between glycosyiphosphatidylinositol-anchored proteins and heterotrimeric G protein α subunits in lymphocytes. Proc Natl Acad Sci USA 93: 6053-6058, 1996.
58. Van den Berg CW, Cinek T, Hallett MB, Horejsi V and Morgan BP: Exogenous CD59 incorporated into U937 cells through its glycosylphosphatidylinositol anchor becomes associated with signalling molecules in a time dependent manner. Biochem Soc Trans 23: 269S, 1995.
59. 2+-signaling competent. J Cell Biol 131: 669-677, 1995.
60. Lund-Johansen F, Olweus J, Symington FW, Arli A, Thompson JS, Vilella R, Skubitz K and Horejsi V: Activation of human monocytes and granulocytes by monoclonal antibodies to glycosylphosphatidylinositol-anchored antigens. Eur J Immunol 23: 2782-2791, 1993.
61. Morgan BP, van den Berg CW, Davies EV, Hallett MB and Horejsi V: Cross-linking of CD59 and of other glycosyl phosphatidylinositol-anchored molecules on neutrophils triggers cell activation via tyrosine kinase. Eur J Immunol 23: 2841-2850, 1993.
62. Cerny J, Stockinger H and Horejsi V: Noncovalent associations of T lymphocyte surface proteins. Eur J Immunol 26: 2335-2343, 1996.
63. Korty PE, Brando C and Shevach EM: CD59 functions as a signal-transducing molecule for human T cell activation. J Immunol 146:4092-4098, 1991.
64. Stefanova I, Horejsi V, Ansotegui IJ, Knapp W and Stockinger H: GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. Science 254: 1016-1019, 1991.
65. Deckert M, Ticchioni M, Mari B, Mary D and Bernard A: The glycosylphosphatidylinositol-anchored CD59 protein stimulates both T cell receptor ζ/ZAP-70-dependent and -independent signaling pathways in T cells. Eur J Immunol 25: 1815-1822, 1995.
66. Miyata T, Yamada N, Iida Y, Nishimura J, Takeda J, Kitani T and Kinoshita T: Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 330: 249-255, 1994.
67. Mahoney JF, Urakaze M, Hall S, De Gasperi R, Chang H-M, Sugiyama E, Warren CD, Borowitz M, Nicholson-Weller A, Rosse WF and Yeh ETH: Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes. Blood 79: 1400-1403, 1992.
68. Rosse WF: Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria. Blood 75: 1595-1601, 1990.
69. Telen MJ and Green AM: The Inab phenotype: characterization of the membrane protein and complement regulatory defect, Blood 74: 437-441, 1989.
70. Yamashina M, Ueda E, Kinoshita T, Takami T, Ojima A, Ono H, Tanaka H, Kondo N, Orii T, Okada N, Okada H, Inoue K and Kitani T: Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 323: 1184-1188, 1990.
71. Motoyama N, Okada N, Yamashina M and Okada H: Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene. Eur J Immunol 22: 2669-2673, 1992.
72. Hatanaka M, Seya T, Matsumoto M, Hara T, Nonaka M, Inoue N, Takeda J and Shimizu A: Mechanisms by which the surface expression of the glycosyl-phosphatidylinositolanchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines. Biochem J 314: 969-976, 1996.
73. Terstappen LWMM, Nguyen M, Lazarus HM and Medof ME: Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation. J Leukoc Biol 52: 652-660, 1992.
74. Väkevä A, Laurila P and Meri S: Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab Invest 67: 608-616, 1992.
75. Guc D, Gulati P, Lemercier C, Lappin D, Birnie GD and Whaley K: Expression of the components and regulatory proteins of the alternative complement pathway and the membrane attack complex in normal and diseased synovium. Rheumatol Int 13: 139-146, 1993.
76. Sayama K, Shiraishi S, Shirakata Y, Kobayashi Y, Okada N, Okada H and Miki Y: Characterization of homologous restriction factor (HRF20) in human skin and leucocytes. Clin Exp Immunol 82: 355-358, 1990.
77. Meri S, Waldmann H and Lachmann PJ: Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 65: 532-537, 1991.
78. Zajicek J, Wing M, Skepper J and Compston A: Human oligodendrocytes are not sensitive to complement. A study of CD59 expression in the human central nervous system. Lab Invest 73: 128-138, 1995.
79. Simpson KL, Houlihan JM and Holmes CH: Complement regulatory proteins in early human fetal life: CD59, membrane co-factor protein (MCP) and decay-accelerating factor (DAF) are differentially expressed in the developing liver. Immunology 80: 183-190, 1993.
80. Holmes CH, Simpson KL, Okada H, Okada N, Waimvright SD, Purcell DFJ and Houlihan JM: Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur J Immunol 22: 1579-1585, 1992.
81. Vanderpuye OA, Labarrere CA and McIntyre JA: Expression of CD59, a human complement system regulatory protein, in extraembryonic membranes. Int Arch Allergy Immunol 101: 376-384, 1993.
82. Simpson KL and Holmes CH: Differential expression of complement regulatory proteins decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 during human spermatogenesis. Immunology 81: 452-461, 1994.
83. Rooney IA, Oglesby TJ and Atkinson JP: Complement in human reproduction: activation and control. Immunol Res 12: 276-294, 1993.
84. Väkevä A, Meri S, Lehto T and Laurila P: Activation of the terminal complement cascade in renal infarction. Kidney Int 47: 918-926, 1995.
85. Davies ME, Horner A, Loveland BE and McKenzie IFC: Upregulation of complement regulators MCP (CD46), DAF (CD55) and protectin (CD59) in arthritic joint disease. Scand J Rheumatol 23: 316-321, 1994.
86. Uesu T, Mizuno M, Inoue H, Tomoda J and Tsuji T: Enhanced expression of decay accelerating factor and CD59/homologous restriction factor 20 on the colonic epithelium of ulcerative colitis. Lab Invest 72: 587-591, 1995.
87. Scallon BJ, Fung W-JC, Tsang TC, Li S, Kado-Fong H, Huang K-S and Kochan JP: Primary structure and functional activity of a phosphatidylinositol-glycan-specific phospholipase D. Science 252: 446-448, 1991.
88. Väkevä A, Morgan BP, Tikkanen I, Helin K, Laurila P and Meri S: Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. Am J Pathol 144: 1357-1368, 1994.
89. Tandon N, Morgan BP and Weetman AP: Expression and function of membrane attack complex inhibitory proteins on thyroid follicülar cells. Immunology 75: 372-377, 1992.
90. Meri S, Mattila P and Renkonen R: Regulation of CD59 expression on the human endothelial cell line EA.hy 926. Eur J Immunol 23: 2511-2516, 1993.
91. Moutabarrik A, Nakanishi I, Namiki M, Hara T, Matsumoto M, Ishibashi M, Okuyama A, Zaid D and Seya T: Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46 (MCP), CD55 (DAF), and CD59 on human vascular endothelial cells. Lymphokine Cytokine Res 12: 167-172, 1993.
92. Rooney IA and Morgan BP: Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. Immunology 76: 541-547, 1992.
93. Brasoveanu LI, Fonsatti E, Visintin A, Pavlovic M, Cattarossi I, Colizzi F, Gasparollo A, Coral S, Horejsi V, Altomonte M and Maio M: Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity. J Clin Invest 100: 1248-1255, 1997.
94. Rooney IA, Atkinson JP, Krul ES, Shonfeld G, Polakoski K, Saffitz JE and Morgan BP: Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organclles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis. J Exp Mcd 177: 1409-1420, 1993.
95. Bjørge L, Jensen TS, Kristoffersen EK, Ulstein M and Matre R: Identification of the complement regulatory protein CD59 in human colostrum and milk. Am J Rcprod Immunol 35: 43-50, 1996.
96. Roddy J, Clark I, Hazleman BL, Compston DAS and Scolding NJ: Cerebrospinal fluid concentrations of the complement MAC inhibitor CD59 in multiple sclerosis and patients with other neurological disorders. J Neurol 241: 557-560, 1994.
97. Bjørge L, Jensen TS, Vedeler CA, Ulvestad E, Kristoffersen EK and Matre R: Soluble CD59 in pregnancy and infancy. Immunol Lett 36: 233-234, 1993.
98. Kooyman DL, Byrne GW, McClellan S, Nielsen D, Tone M, Waldmann H, Coffman TM, McCurry KR, Platt JL and Logan JS: In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 269: 89-92, 1995.
99. Väkevä A, Jauhiainen M, Ehnholm C, Lehto T and Meri S: High-density lipoproteins can act as carriers of glycophosphoinositol lipid-anchored CD59 in human plasma. Immunolocy 82: 28-33, 1994.
100. Sayama K, Shiraishi S and Miki Y: Distribution of complement regulators (CD46, CD55 and CD59) in skin appendages, and in benign and malignant skin neoplasms. Br J Dermatol 127: 1-4, 1992.
101. Brasoveanu LI, Altomonte M, Fonsatti E, Coral S, Visintin A, Cattelan A, Natali PG and Maio M: Role of protectin (CD59) as regulator of complement-mediated lysis of melanoma cells: relevance in immunotherapy. In: Immunology of Human Melanoma: Tumor-Host Interaction and Immunotherapy. Maio M (ed). IOS Press, Ohmsha, Washington, DC, pp185-194, 1996.
102. Brasoveanu LI, Altomonte M, Gloghini A, Fonsatti E, Coral S, Gasparollo A, Montagner R, Cattarossi I, Simonelli C, Cattelan A, Attadia V, Carbone A and Maio M: Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity. Int J Cancer 61: 548-556, 1995.
103. Goslings WR, Blom DJ, De Waard-Siebinga I, van Beelen E, Claas FHJ, Jager MJ and Gorter A: Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas. Invest Ophtalmol Vis Sci 37: 1884-1891, 1996.
104. Jarvis GA, Li J, Hakulinen J, Brady KA, Nordling S, Dahiya R and Meri S: Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer 71: 1049-1055, 1997.
105. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ and Dalmasso AP: Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 149: 129-142, 1996.
106. Hakulinen J and Meri S: Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab Invest 71: 820-827, 1994.
107. Yamakawa M, Yamada K, Tsuge T, Ohrui H, Ogata T, Dobashi M and Imai Y: Protection of thyroid cancer cells by complement-regulatory factors. Cancer 73: 2808-2817, 1994.
108. Shinoura N, Heffelfinger SC, Miller M, Shamraj OI, Miura N-HC, Larson JJ, De Tribolet N, Warnick RE, Tew JJ and Menon AG: RNA expression of complement regulatory proteins in human brain tumors. Cancer Lett 86: 143-149, 1994.
109. Mäenpää A, Junnikkala S, Hakulinen J, Timonen T and Meri S: Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am J Pathol 148: 1139-1152, 1996.
110. Koretz K, Brüderlein S, Henne C and Möller P: Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium. Br J Cancer 68: 926-931, 1993.
111. Bjørge L, Vedeler CA, Ulvestad E and Matre R: Expression and function of CD59 on colonic adenocarcinoma cells. Eur J Immunol 24: 1597-1603, 1994.
112. Simpson KL, Jones A, Norman S and Holmes CH: Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease. Am J Pathol 151: 1455-1467, 1997.
113. Bjørge L, Jensen TS, Ulvestad E, Vedeler CA and Matre R: The influence of tumor necrosis factor-α, interleukin-1ß and interferon-γ on the expression and function of the complement regulatory protein CD59 on the human colonic adenocarcinoma cell line HT29. Scand J Immunol 41: 350-356, 1995.
114. Lehto T and Meri S: Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8. J Immunol 151: 4941-4949, 1993.
115. Bjørge L and Matre R: Down-regulation of CD59 (protectin) expression on human colorectal adenocarcinoma cell lines by levamisole. Scand J Immunol 42: 512-516, 1995.
116. Kuraya M, Yefenof E, Klein G and Klein E: Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis. Eur J Immunol 22: 1871-1876, 1992.
117. Sedlak J, Hunakova L, Duraj J, Grofova M and Chorvath B: Modulation of protectin (CD59 antigen) cell surface expression on human neoplastic cell lines. Neoplasma 40: 337-340, 1993.
118. Marchbank KJ, Morgan BP and van den Berg CW: Regulation of CD59 expression on K562 cells: effects of phorbol myristate acetate, cross-linking antibody and non-lethal complement attack. Immunology 85: 146-152, 1995.